All In Biotech

Drug Trial Radar · NCT02649790

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications

Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

277

Planned (sponsor's estimate)

Start

Jan 2016

Primary completion

Aug 31, 2024

Study completion Dec 23, 2024

Sponsor

Lead sponsor
Karyopharm Therapeutics IncIndustry
Sponsor type
Industry
First posted
Jan 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed intermediate/high-risk MDS. Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.

Conditions

  • Relapsed/Refractory Multiple Myeloma (RRMM)
  • Metastatic Colorectal Cancer (mCRC)
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Higher-Risk Myelodysplastic Syndrome (HR-MDS)
  • Acute Myeloid Leukemia (AML)
  • Newly Diagnosed Intermediate/High-Risk MDS

Interventions

  • KPT-8602Drug

    Participants will receive KPT-8602 oral tablets.

  • ASTX727Drug

    ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.

  • DexamethasoneDrug

    Participants will receive dexamethasone oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A1, A2, B, C, D, E, F: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Time frame: Approximately 4 weeks
  2. Part A1, A2, B, C, D, E, F: Overall Response Rate (ORR)Time frame: Approximately 8 years
  3. Part A1, A2, B, C, D, E, F: Duration of Response (DOR)Time frame: Approximately 8 years
  4. Part A1, A2, B, C, D, E, F: Progression-free Survival (PFS)Time frame: Approximately 8 years
  5. Part A1, A2, B, C, D, E, F: Overall Survival (OS)Time frame: Approximately 8 years
  6. Part A1, A2, B, C, D, E, F: Clinical Benefit Rate (CBR)Time frame: Approximately 8 years
  7. Part A1, A2, B, C, D, E, F: Duration of Clinical Benefit Rate (CBR)Time frame: Approximately 8 years
  8. Part A1, A2, B, C, D, E, F: Disease Control Rate (DCR)Time frame: Approximately 8 years
  9. Part A1, A2, B, C, D, E, F: Duration of DCRTime frame: Approximately 8 years
  10. Part F Phase 2: ORRTime frame: Approximately 8 years
  11. Part G: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Time frame: Approximately 8 years
  12. Part H: 2- Year Progression-free Survival (PFS)Time frame: Approximately Up to 2 years

Locations

46 sites in 5 countries. Site status is shown where the registry gives one.

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • Oncology Institute of Hope and Innovation

    Pasadena, California

  • Rocky Mountain Regional VA Medical Center

    Aurora, Colorado

  • Sarah Cannon Cancer Center - (Colorado Blood Cancer Institute)

    Denver, Colorado

  • (USO) Rocky Mountain Cancer Centers

    Littleton, Colorado

  • Moffitt Cancer Center

    Tampa, Florida

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • Sarah Cannon Cancer Center (HCA Midwest KC)

    Kansas City, Missouri

  • Callahan Cancer Center

    North Platte, Nebraska

  • John Theurer Cancer Center at Hackensack UMC

    Hackensack, New Jersey

  • University of New Mexico

    Albuquerque, New Mexico

  • Weill Cornell Medical College

    New York, New York

  • (USO) Oncology Hematology Care

    Cincinnati, Ohio

  • Ohio State University, The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio

  • University of Pennsylvania Abramson Cancer Center Clinical Research Unit

    Philadelphia, Pennsylvania

  • Baptist Cancer Center

    Memphis, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • (USO) Texas Oncology Austin - Midtown

    Austin, Texas

  • (USO) Texas Oncology (Dallas)

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • (USO) Texas Oncology (Tyler)

    Tyler, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • University of Virginia

    Charlottesville, Virginia

  • (USO) Virginia Cancer Specialists

    Fairfax, Virginia

  • University of Washington

    Seattle, Washington

  • (USO) Compass oncology

    Vancouver, Washington

  • McMaster - Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Research

    Toronto, Ontario, Canada

  • MUHC GLEN Site Cedars - Cancer Centre

    Montreal, Quebec, Canada

  • China, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • CHU Nantes

    Nantes, France

  • Hôpital Cochin APHP

    Paris, France

  • Hôpital Necker

    Paris, France

  • Hôpital St Louis

    Paris, France

  • CHU de Bordeaux

    Pessac, France

  • CHU de Tours

    Tours, France

  • CHRU de Nancy

    Vandœuvre-lès-Nancy, France

  • Clínica Universidad de Navarra

    Barcelona, Spain

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.